Table 2. Treatment Effects of RA and SA From Baseline to 4 Weeks Posttreatment and 8 Weeks of Follow-Up.
| Outcome assessment | RA group (n = 40) | SA group (n = 38) | ||
|---|---|---|---|---|
| Change from baseline, mean (95% CI) | P value | Change from baseline, mean (95% CI) | P value | |
| PDSS | ||||
| Posttreatment | 29.65 (24.65 to 34.65) | <.001 | 10.47 (5.35 to 15.60) | <.001 |
| Follow-up | 25.35 (20.35 to 30.35) | <.001 | 5.68 (0.56 to 10.81) | .03 |
| ESS | ||||
| Posttreatment | −3.78 (−4.82 to −2.73) | <.001 | −2.08 (−3.15 to −1.01) | <.001 |
| Follow-up | −3.30 (−4.34 to −2.26) | <.001 | −1.05 (−2.12 to 0.02) | .05 |
| UPDRS | ||||
| Posttreatment | −14.53 (−17.73 to −11.32) | <.001 | −2.95 (−6.24 to 0.35) | .08 |
| Follow-up | −14.28 (−17.48 to −11.07) | <.001 | −0.58 (−3.87 to 2.71) | .73 |
| UPDRS-III | ||||
| Posttreatment | −6.88 (−9.01 to −4.73) | <.001 | −3.34 (−5.53 to −1.14) | .003 |
| Follow-up | −6.38 (−8.51 to −4.23) | <.001 | −2.24 (−4.43 to −0.04) | .046 |
| NMSS | ||||
| Posttreatment | −12.28 (−16.00 to −8.55) | <.001 | −5.10 (−8.92 to −1.29) | .009 |
| Follow-up | −8.65 (−12.37 to −4.92) | <.001 | −3.18 (−7.00 to 0.63) | .10 |
| HAM-A | ||||
| Posttreatment | −5.28 (−6.76 to −3.78) | <.001 | −1.74 (−3.26 to −0.21) | .03 |
| Follow-up | −1.30 (−2.79 to 0.19) | .09 | 3.61 (2.08 to 5.13) | <.001 |
| PDQ-39 | ||||
| Posttreatment | −14.75 (−18.62 to −10.88) | <.001 | −4.74 (−8.70 to −0.77) | .02 |
| Follow-up | −7.55 (−11.42 to −3.68) | <.001 | 2.42 (−1.54 to 6.39) | .23 |
Abbreviations: ESS, Epworth Sleepiness Scale; HAM-A, Hamilton Anxiety Rating Scale; NMSS, Non-Motor Symptoms Scale; PDQ-39, 39-item Parkinson Disease Questionnaire; PDSS, Parkinson Disease Sleep Scale; RA, real acupuncture; SA, sham acupuncture; UPDRS, Unified Parkinson Disease Rating Scale; UPDRS-III, section 3 of the Unified Parkinson Disease Rating Scale.